Neuroprotective implant for treatment of glaucoma in phase II trial

June 10, 2019
Julianne Mobilian

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Related Content:

ASCRS | Retina | Glaucoma